Why the UK approved AstraZeneca despite its rubber band immunity effect

Why did the UK approve AstraZeneca despite ‘rubber band immunity’
Less effective than Pfizer Modena, but better than the flu vaccine
In addition to the ‘homemade vaccine’, the advantages of price and distribution … Required to expand vaccination
Rapid rise in number of UK corona infections in ‘mutation occurrence’ also affects rapid approval

(London = Yonhap News) Correspondent Park Daehan = The UK government approved the urgent use of a new vaccine against coronavirus infection (Corona 19) developed by the University of Oxford and the multinational pharmaceutical company AstraZeneca for the first time in the world on the 30th (local time).
However, AstraZeneca is reported to have not even applied for approval from the European Medicines Agency (EMA) or the United States Food and Drug Administration (FDA).
Consequently, the approval from the European Union (EU) or the United States is expected to be covered after February next year at the earliest.
The UK approval of the world’s first Oxford-AstraZeneca vaccine after the Pfizer-Bioentech COVID-19 vaccine is followed by several reviews.

◇ The possibility of using vaccines is sufficient even though it is less effective than Pfizer and Moder.
The vaccine, developed by the University of Oxford and produced by AstraZeneca, was initially one of the most promising vaccine candidates against Corona 19.
It was this vaccine that was expected to be developed first.
However, the AstraZeneca vaccine was controversial due to its ‘rubber band immunity effect’ and the omission of key data and information.
In particular, it was noted as a weakness that the immunity effect is less than that of Pfizer, modder, or vaccines that have already been approved in the United States.
The Pfizer vaccine is 95% immune effective and 94.5% Modern, but AstraZeneca drops to 70.4% on average.
However, participants who took half the dose of the vaccine first and received a full dose a month later increased the preventive effect to 90%.
In both cases, the prophylactic effect of those who took the full dose in a single dose was 62%.
This is a situation that requires further investigation and investigation.
The UK government approved the use of the AstraZeneca vaccine in two full doses per dose.
In this case, the preventive effect is 62%, but the effect is reported to increase with increasing dosing interval between the first and second doses.
Additionally, none of those who contracted COVID-19 after receiving the AstraZeneca vaccine had a serious condition and it made their symptoms worse.
The effectiveness of the seasonal flu vaccine is generally about 40 to 60% because the virus evolves every year.
The World Health Organization (WHO) believes that the COVID-19 vaccine will be available only when the effectiveness of the vaccine is at least 50%.
Anthony Pouch, director of the National Institute of Allergy and Infectious Diseases, also said that the Corona 19 vaccine, which is only 50-60% effective, is fine.
In other words, the UK government considers the AstraZeneca vaccine to have no problem working as a vaccine itself, although it is less effective than Pfizer, Moder or the vaccine.

◇ Low price and easy distribution … Suitable for large doses
Additionally, AstraZeneca vaccines have price and distribution advantages that can counteract the effects of Pfizer, Moder, and vaccines.
Pfizer Corona 19 vaccine must be transported at minus 70 degrees ± 10 degrees Celsius.
If the vaccine is thawed at the vaccination site, it can be stored for up to 5 days at 2-8 degrees Celsius, which is a normal refrigerator.
As storage and transportation are difficult, there are cases of vaccination delays in countries that have received Pfizer vaccines such as Germany and Spain.
The UK, which started the world’s first Pfizer vaccination on day 8, also vaccinated 800,000 people over 20 days.
On the other hand, AstraZeneca is very inexpensive and can transport, store and administer the vaccine for at least 6 months at a normal refrigerator temperature of 2-8 degrees Celsius.
Large-scale vaccination is essential to ensure the immunity of the population, but without AstraZeneca’s approval, the Pfizer vaccine alone is inevitably insufficient.
Previously, the Daily Telegraph predicted that if the government approves the use of the AstraZeneca vaccine, 2 million people will be vaccinated with the AstraZeneca and Pfizer vaccines within two weeks.
To this end, the UK government is working to convert sports venues and conference rooms into large-scale vaccine centers.
In addition to large-scale vaccine centers, 1 million people are expected to be vaccinated weekly if the vaccine is available at regional doctors (GPs) and pharmacies that do not have separate storage facilities.
The key is to secure enough stock.
The number of pre-orders for Pfizer vaccines insured by the UK government is 40 million doses, and 20 million people receive two doses.
The amount of pre-insured modders or supplies is only 7 million times, which can be used by 3.5 million people.
On the other hand, the University of Oxford in the United Kingdom and AstraZeneca based in the United Kingdom and Sweden jointly developed this product, which is actually a “native vaccine”, and sold 100 million doses in advance.
Of these, 40 million servings are expected to be available by the end of March next year.
After all, it would be difficult for the entire UK population to complete vaccination in the near future without the approval of the AstraZeneca vaccine.

◇ With the appearance of mutations, corona infection increases in the UK … Vaccination
In the UK, the rapid rise in infected people goes unnoticed due to the recent COVID-19 mutation.
The number of new confirmed cases per day surpassed the 40,000 mark for the first time in history on the 28th (41,385) and the 50,000 mark on the 29th (53,135), one day.
Countries around the world are responding with restrictions or restrictions on entry to the UK, which was the first to reveal the discovery of the mutant virus.
In this situation, an analysis suggests that only the expansion of vaccines on a large scale through the approval of the AstraZeneca vaccine can be a breakthrough.
UK regulators, however, emphasize that they have not shortened the process or neglected validation to approve the AstraZeneca vaccine.
Dr Jun Lane, Director of the MHRA, an independent regulator recommending the use of the vaccine to the UK government, said: “We have been constantly looking for all the data on the safety, effectiveness and quality of the AstraZeneca vaccine since the moment it’s available. “And he cleared up some concerns.
[email protected]
(The end)

<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>